All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2007-02-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.2006.067660PMID 17324968PMCID PMC1955107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• Infectious causes of death in patients with rheumatoid arthritis: an autopsy study

  2006cited by this paper
• Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s

  2005cited by this paper
• Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

  2005cited by this paper
• Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

  2005cited by this paper
• Rheumatoid arthritis registries in Sweden.

  2005cited by this paper
• Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group

  2005cited by this paper
• Cardiovascular death in rheumatoid arthritis: a population-based study.

  2005cited by this paper
• Relationship Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study

  2005cited by this paper
• Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.

  2004cited by this paper
• Rheumatoid arthritis and accelerated atherogenesis.

  2004cited by this paper
• Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis.

  2004cited by this paper
• Declines in Mortality From Acute Myocardial Infarction in Successive Incidence and Birth Cohorts of Patients With Rheumatoid Arthritis

  2004cited by this paper
• Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.

  2003cited by this paper
• Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects.

  2003cited by this paper
• PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing

  2003cited by this paper
• Infections and anti–tumor necrosis factor α therapy

  2003cited by this paper
• Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis

  2003cited by this paper
• Infections and anti-tumor necrosis factor alpha therapy.

  2003cited by this paper
• Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

  2003cited by this paper
• Increased risk of tuberculosis in patients with rheumatoid arthritis.

  2003cited by this paper
• Infections and biological therapy in rheumatoid arthritis.

  2003cited by this paper
• Increased Prevalence of Severe Subclinical Atherosclerotic Findings in Long-Term Treated Rheumatoid Arthritis Patients Without Clinically Evident Atherosclerotic Disease

  2003cited by this paper
• Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity

  2003cited by this paper
• Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.

  2002cited by this paper
• Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis

  2002cited by this paper
• Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

  2002cited by this paper
• Side effects of anti-TNF therapy: current knowledge.

  2002cited by this paper
• Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women’s Health Study

  2002cited by this paper
• Anti–Tumor Necrosis Factor-&agr; Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis

  2002cited by this paper
• Infliximab: additional safety data from an open label study.

  2002cited by this paper
• Coronary artery disease and rheumatoid arthritis

  2002cited by this paper
• Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity.

  2001cited by this paper
• High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

  2001cited by this paper
• Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.

  2000cited by this paper
• No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset

  2000cited by this paper
• Invited commentary: propensity scores.

  1999cited by this paper
• Mortality in rheumatoid arthritis patients with disease onset in the 1980s

  1999cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset.

  1999cited by this paper
• Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well.

  1998cited by this paper
• Accuracy of Death Certificates for Coding Coronary Heart Disease as the Cause of Death

  1998cited by this paper
• Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

  1998cited by this paper
• Tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta down-regulate intercellular adhesion molecule (ICAM)-2 expression on the endothelium.

  1998cited by this paper
• Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

  1997cited by this paper
• Mortality in rheumatoid arthritis.

  1995cited by this paper
• Is the apparent rise in cancer mortality in the elderly real? analysis of changes in certification and coding of cause of death in England and Wales, 1970–1990

  1995cited by this paper
• Effects of TNF-alpha on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs.

  1994cited by this paper
• Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina.

  1994cited by this paper
• The mortality of rheumatoid arthritis.

  1994cited by this paper
• Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients.

  1990cited by this paper
• Mortality in rheumatoid arthritis.

  1988cited by this paper

• What to do when the first TNF inhibitor fails in rheumatoid arthritis: stratified expert recommendations from a scoping review and Delphi consensus.

  2026cites this paper
• Insights Into Late‐Onset Rheumatoid Arthritis (LORA): Characteristics (Clinical and Imaging), Comorbidities, and Therapeutic Targets

  2026cites this paper
• Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use

  2025cites this paper
• Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large‐scale meta‐analysis in immune‐mediated inflammatory diseases

  2025cites this paper
• Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis

  2024cites this paper
• Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

  2024cites this paper
• Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases

  2024cites this paper
• Mortality Trends Among Patients with Rheumatoid Arthritis in Western Australia

  2023cites this paper
• Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.

  2023cites this paper
• Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review

  2023cites this paper
• Incidence and Determinants of Infection in Rheumatoid Arthritis Patients Treated with Golimumab in Real-World After a Median Follow-up Time of 27 Months.

  2023cites this paper
• Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options

  2023cites this paper
• Safety of Anti-TNFs in Patients with Immune-Mediated Disease

  2022cites this paper
• All-cause and cause-specific mortality of patients with rheumatoid arthritis in Korea: A nation-wide population-based study.

  2021cites this paper
• Mortality in Korean Patients With Rheumatoid Arthritis

  2021cites this paper
• Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

  2021cites this paper
• Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project

  2021cites this paper
• Cardiac manifestations of rheumatic diseases.

  2021cites this paper
• Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High‐Risk Lesions

  2020cites this paper
• Cardiovascular effects of biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

  2020cites this paper
• Analysis of Effectiveness, Safety and Optimization of Tocilizumab in a Cohort of Patients With Rheumatoid Arthritis in Clinical Practice

  2019cites this paper
• Casual effect of methotrexate+etanercept/infliximab on survival of patients with rheumatoid arthritis

  2019cites this paper
• Implementing New Methodology for Earthquake Risk Mitigation of Developing Countries with High Hazard

  2018cites this paper
• The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?

  2018cites this paper
• Comorbidity in Rheumatic Diseases

  2017cites this paper
• Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach

  2017cites this paper
• Revue systématique des registres de polyarthrites rhumatoïdes sous biothérapie dans le monde et méta-analyse sur les données de tolérance

  2017cites this paper
• Pathogenetic insights from the treatment of rheumatoid arthritis.

  2017cites this paper
• Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register

  2017cites this paper
• Analysis of effectiveness, safety and optimization of tocilizumab in a cohort of patients with rheumatoid arthritis in clinical practice.

  2017cites this paper
• Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers.

  2017cites this paper
• Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review

  2016cites this paper
• The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis

  2016cites this paper
• Características de los tratamientos biológicos en enfermedades reumáticas en Argentina: quinto informe del registro BIOBADASAR

  2016cites this paper
• Risk factors for surgical site infection and delayed wound healing after orthopedic surgery in rheumatoid arthritis patients

  2016cites this paper
• Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

  2016cites this paper
• Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis

  2016cites this paper
• Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents.

  2016cites this paper
• Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan

  2016cites this paper
• Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis

  2016cites this paper
• Influence of demographic and clinical factors on the mortality rate of a rheumatoid arthritis cohort: A 20-year survival study.

  2016cites this paper
• Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources.

  2015cites this paper
• Clinical repercussions of introducing biological therapies: the well-controlled patient.

  2015cites this paper
• Premature Mortality: A Neglected Outcome in Rheumatic Diseases?

  2015cites this paper
• Frecuencia de mortalidad en pacientes con artritis reumatoidea en un centro de reumatología de Argentina

  2015cites this paper
• Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis

  2015cites this paper
• Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention

  2015cites this paper
• The 2013 ACC/AHA 10-year atherosclerotic cardiovascular disease risk index is better than SCORE and QRisk II in rheumatoid arthritis: is it enough?

  2015cites this paper
• Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients.

  2015cites this paper
• Review articleSafe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritidesSegurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartrites

  2015cites this paper
• All-cause Mortality Associated with TNF-α Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials.

  2015cites this paper
• Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis , ankylosing spondylitis and psoriatic arthritis

  2015cites this paper
• The Impact of Traditional Cardiovascular Risk Factors on Cardiovascular Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

  2015cites this paper
• Clinical repercussions of introducing biological therapies: the well-controlled patient.

  2015cites this paper
• Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada

  2015cites this paper
• [Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].

  2015cites this paper
• The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

  2015cites this paper
• The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB)

  2014cites this paper
• A systematic review of the infl uence of anti-TNF on infection rates in patients with rheumatoid arthritis

  2014cites this paper
• Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis

  2014cites this paper
• ESTUDIO MULTICÉNTRICO LONGITUDINAL DE DEPLECIÓN DE LINFOCITOS B EN LUPUS ERITEMATOSO SISTÉMICO REFRACTARIO: ESTUDIO LESIMAB

  2014cites this paper
• Cardiovascular disease in rheumatoid arthritis.

  2014cites this paper
• Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

  2014cites this paper
• Adverse reactions to biologic agents and their medical management

  2014cites this paper
• Anti-TNF Therapy: 20 Years from Our First Therapeutic Adventure

  2014cites this paper
• Artritis psoriásica: Contribuciones al conocimiento de su patogenia, de sus comorbilidades y al perfil de seguridad de su tratamiento

  2014influential citation
• BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries.

  2014cites this paper
• The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

  2014cites this paper
• Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.

  2014cites this paper
• Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis

  2014cites this paper
• A clinical and health economical observational study of anti-tumor necrosis factor therapy in the treatment of rheumatoid arthritis in Finland

  2014cites this paper
• Safety of B-Cell Targeted Therapies

  2014cites this paper
• Increased cardiovascular risk in patients with rheumatoid arthritis: an overview

  2014cites this paper
• Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0

  2014cites this paper
• Anti-TNF therapy and malignancy in patients with rheumatoid arthritis : studies on cancer incidence, recurrence and survival

  2014cites this paper
• Rheumatoid arthritis and cardiac disease

  2014cites this paper
• Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review.

  2014cites this paper
• Coronary and Abdominal Aorta Calcification in Rheumatoid Arthritis: Relationships with Traditional Cardiovascular Risk Factors, Disease Characteristics, and Concomitant Treatments

  2014cites this paper
• Safety of Immunosuppressive Therapy for Eye Diseases

  2014cites this paper
• The Epidemiology of Rheumatoid Arthritis in Ontario, Canada

  2014cites this paper
• From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

  2014cites this paper
• [Cost-effectiveness analysis of etanercept compared with other biologic therapies in the treatment of rheumatoid arthritis].

  2013cites this paper
• Comment about the article by Bisson-Vaivre et al.: "The role of HLA and KIR in anti-TNF therapy".

  2013cites this paper
• Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

  2013cites this paper
• Automated radiofrequency-based US measurement of common carotid intima-media thickness in RA patients treated with synthetic vs synthetic and biologic DMARDs.

  2013cites this paper
• A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis.

  2013cites this paper
• Cardiovascular disease management in RA.

  2013cites this paper
• The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.

  2013cites this paper
• Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account.

  2013cites this paper
• Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis.

  2013cites this paper
• Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidence-Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis

  2013cites this paper
• Factores asociados al desarrollo de efectos secundarios en pacientes con artritis reumatoide tratados con anti-factor de necrosis tumoral alfa

  2013cites this paper
• Commentaire de l’article par Bisson-Vaivre et al., « Rôle du HLA et du KIR dans le traitement par anti-TNF »

  2013cites this paper
• OP-BRHE120218 376..381

  2013cites this paper
• Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.

  2013cites this paper
• Evaluación de la actividad inflamatoria mediante ultrasonografía en la artritis reumatoide

  2013cites this paper
• Changes in Lipoproteins Associated with Treatment with Methotrexate or Combination Therapy in Early Rheumatoid Arthritis: Results from the TEAR Trial

  2013cites this paper
• Etanercept in the treatment of rheumatoid arthritis

  2013cites this paper
• The safety and efficacy, and recommendations for the use of biologic drugs in the UK military rheumatology population

  2013cites this paper
• Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

  2013cites this paper